Patents by Inventor Paul Rafferty

Paul Rafferty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180214844
    Abstract: A particulate composition said composition comprises a metal carbonate and/or a metal bicarbonate and a compound of aluminium, characterised in that the weight ratio of metal carbonate plus metal bicarbonate compounds to said compound of aluminium is at least 3:1. The composition is useful for removing halogenated compounds from a hydrocarbon-containing process stream.
    Type: Application
    Filed: July 12, 2016
    Publication date: August 2, 2018
    Inventors: David Jonathan DAVIS, Paul RAFFERTY, Elaine Margaret VASS
  • Patent number: 9873617
    Abstract: A method for producing a sulphided copper sorbent includes the steps of: (i) contacting a sorbent precursor material containing one or more sulphidable copper compounds, with a sulphiding gas stream including hydrogen sulphide to form a sulphided sulphur-containing sorbent material, and (ii) subjecting the sulphided sulphur-containing sorbent material to a heating step in which it is heated to a temperature above that used in the sulphiding step and ?110° C., under an inert gas selected from nitrogen, argon, helium, carbon dioxide, methane, and mixtures thereof, the inert gas optionally including hydrogen sulphide. The method provides sulphided copper sorbents that have reduced levels of elemental sulphur.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: January 23, 2018
    Assignee: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
    Inventors: Matthew John Cousins, David Davis, Paul Rafferty, Sarah Ridley, Alan Gordon Tapster
  • Publication number: 20150060729
    Abstract: A method for producing a sulphided copper sorbent includes the steps of: (i) contacting a sorbent precursor material containing one or more sulphidable copper compounds, with a sulphiding gas stream including hydrogen sulphide to form a sulphided sulphur-containing sorbent material, and (ii) subjecting the sulphided sulphur-containing sorbent material to a heating step in which it is heated to a temperature above that used in the sulphiding step and ?110° C., under an inert gas selected from nitrogen, argon, helium, carbon dioxide, methane, and mixtures thereof, the inert gas optionally including hydrogen sulphide. The method provides sulphided copper sorbents that have reduced levels of elemental sulphur.
    Type: Application
    Filed: February 25, 2013
    Publication date: March 5, 2015
    Applicant: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
    Inventors: Matthew John Cousins, David Davis, Paul Rafferty, Sarah Ridley, Alan Gordon Tapster
  • Patent number: 8273736
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: September 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • Patent number: 7863444
    Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: January 4, 2011
    Assignee: Abbott Laboratories
    Inventors: David Calderwood, Lee Arnold, Hormoz Mazdiyasni, Gavin C. Hirst, Bojuan B. Deng, David N. Johnston, Paul Rafferty, Gerald B. Tometzki, Helen L. Twigger, Rainer Munschauer
  • Patent number: 7737160
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 15, 2010
    Assignee: Abbott Laboratories Inc.
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • Publication number: 20100069371
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: November 20, 2009
    Publication date: March 18, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • Patent number: 7468371
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: December 23, 2008
    Assignee: Abbott Laboratories Inc.
    Inventors: Lee D. Arnold, Jürgen Dinges, Richard W. Dixon, Stevan W. Djuric, Anna M. Ericsson, Kimba Fischer, Alan F. Gasiecki, Vijaya J. Gracias, James H. Holms, Makoto Takeshita, Michael R. Michaelides, Melanie A. Muckey, Paul Rafferty, Douglas H. Steinman, Carol K. Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Q. Zhang
  • Patent number: 7358267
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: April 15, 2008
    Assignee: Amgen Inc.
    Inventors: M. Catherine Amaral, Jin-Long Chen, Juan C. Jaen, David N. Johnston, Paul Rafferty
  • Publication number: 20080076924
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: June 29, 2007
    Publication date: March 27, 2008
    Inventors: Patrick Betschmann, William Carroll, Anna Ericsson, Shannon Fix-Stenzel, Michael Friedman, Gavin Hirst, Nathan Josephsohn, Biqin Li, Arturo Perez-Medrano, Michael Morytko, Paul Rafferty, Haipeng Chen
  • Patent number: 7332497
    Abstract: The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, and R3 are defined as described herein.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: February 19, 2008
    Assignee: Abbott GmbH & Co KG
    Inventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
  • Publication number: 20070155776
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: February 15, 2007
    Publication date: July 5, 2007
    Inventors: Patrick Betschmann, Andrew Burchat, David Calderwood, Michael Curtin, Steven Davidsen, Heather Davis, Robin Frey, Howard Heyman, Gavin Hirst, Peter Hrnciar, Michael Michaelides, Melanie Muckey, Kelly Mullen, Paul Rafferty, Carol Wada
  • Patent number: 7202363
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: April 10, 2007
    Assignee: Abbott Laboratories
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • Patent number: 7071199
    Abstract: The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: July 4, 2006
    Assignee: Abbott GmbH & CCo. KG
    Inventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Helen Twigger, Stephen St. Gallay
  • Patent number: 7060822
    Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: June 13, 2006
    Assignee: Abbott GmbH & Co. KG
    Inventors: Lee Arnold, Marina Moran Moset, Jose Maria Castellano Berlanga, Isabel Fernandez, David J. Calderwood, Paul Rafferty
  • Patent number: 7049312
    Abstract: Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2— R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent R3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: May 23, 2006
    Assignee: Abbott GmbH & Co. KG
    Inventors: Paul Rafferty, David Calderwood, Lee Arnold, Beatriz Gonzalez Pascual, Jose L. Ortego Martinez, Maria J. Perez de Vega, Isabel Fernandez
  • Publication number: 20060014816
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: March 24, 2005
    Publication date: January 19, 2006
    Inventors: Lee Arnold, Jurgen Dinges, Richard Dixon, Stevan Djuric, Anna Ericsson, Kimba Fischer, Alan Gasiecki, Vijaya Gracias, James Holms, Makoto Takeshita, Michael Michaelides, Melanie Muckey, Paul Rafferty, Douglas Steinman, Carol Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Zhang
  • Publication number: 20050215608
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and type II diabetes, and associated diseases.
    Type: Application
    Filed: June 27, 2002
    Publication date: September 29, 2005
    Inventors: M. Amaral, Jin-Long Chen, Juan Jaen, David Johnston, Paul Rafferty
  • Patent number: 6921763
    Abstract: The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: July 26, 2005
    Assignee: Abbott Laboratories
    Inventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
  • Publication number: 20050043347
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: July 26, 2004
    Publication date: February 24, 2005
    Inventors: Patrick Betschmann, Andrew Burchat, David Calderwood, Michael Curtin, Steven Davidsen, Heather Davis, Robin Frey, Howard Heyman, Gavin Hirst, Peter Hrnciar, Michael Michaelides, Melanie Muckey, Paul Rafferty, Carol Wada